BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
-16.82%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.12B
AUM Growth
+$3.12B
(-17%)
Cap. Flow
+$70.8M
Cap. Flow
% of AUM
2.27%
Top 10 Holdings %
Top 10 Hldgs %
64.02%
Holding
36
New
4
Increased
20
Reduced
3
Closed
2
Top Buys
| 1 |
Moderna
MRNA
|
$73.1M |
| 2 |
Agios Pharmaceuticals
AGIO
|
$31.4M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$29.1M |
| 4 |
Scholar Rock
SRRK
|
$25M |
| 5 |
Kezar Life Sciences
KZR
|
$19.3M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$114M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$49.2M |
| 3 |
CELG
Celgene Corp
CELG
|
$43.6M |
| 4 |
Gilead Sciences
GILD
|
$38.9M |
| 5 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$4.71M |
Sector Composition
| 1 | Healthcare | 96.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $473M | 15.14% | 8,741,334 +75,000 | +0.9% | +$4.05M |
|
2
Incyte
INCY
$16.5B
| $242M | 7.76% | 3,808,322 | – | – |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $239M | 7.65% | 3,343,090 +185,000 | +6% | +$13.2M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $227M | 7.28% | 1,370,445 | – | – |
|
5
Esperion Therapeutics
ESPR
$448M
| $156M | 5% | 3,392,964 +110,000 | +3% | +$5.06M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $148M | 4.73% | 2,303,875 -680,423 | -23% | -$43.6M |
|
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $133M | 4.25% | 2,878,134 +680,203 | +31% | +$31.4M |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $132M | 4.22% | 1,375,229 +303,856 | +28% | +$29.1M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $128M | 4.1% | 1,314,428 | – | – |
|
10
Halozyme
HALO
$8.56B
| $122M | 3.9% | 8,322,860 +75,000 | +0.9% | +$1.1M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $115M | 3.67% | 1,571,389 +200,851 | +15% | +$14.6M |
|
|
RDUS
12
DELISTED
Radius Health, Inc.
RDUS
| $111M | 3.54% | 6,710,276 +120,000 | +2% | +$1.98M |
|
13
argenx
ARGX
$43.6B
| $85M | 2.72% | 884,739 +150,000 | +20% | +$14.4M |
|
|
14
Gilead Sciences
GILD
$140B
| $83.3M | 2.67% | 1,332,204 -622,392 | -32% | -$38.9M |
|
|
15
Moderna
MRNA
$9.37B
| $73.1M | 2.34% | +4,785,681 | New | +$73.1M |
|
|
AKCA
16
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $71.9M | 2.3% | 2,386,471 | – | – |
|
17
Wave Life Sciences
WVE
$1.53B
| $61.6M | 1.97% | 1,465,002 +80,000 | +6% | +$3.36M |
|
|
MYOV
18
DELISTED
Myovant Sciences Ltd.
MYOV
| $59M | 1.89% | 3,597,882 +30,000 | +0.8% | +$492K |
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $58M | 1.86% | 575,719 +30,000 | +5% | +$3.02M |
|
20
Exelixis
EXEL
$10.1B
| $55.8M | 1.79% | 2,835,000 +50,000 | +2% | +$983K |
|
21
Nektar Therapeutics
NKTR
$568M
| $45.4M | 1.45% | 1,380,975 +535,975 | +63% | +$17.6M |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $42.9M | 1.37% | 877,266 +367,266 | +72% | +$17.9M |
|
23
MacroGenics
MGNX
$112M
| $41.7M | 1.34% | 3,283,272 +292,860 | +10% | +$3.72M |
|
|
24
Scholar Rock
SRRK
$3.14B
| $29.4M | 0.94% | 1,279,978 +1,090,021 | +574% | +$25M |
|
|
ALDR
25
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $28.4M | 0.91% | 2,766,008 +500,000 | +22% | +$5.13M |
|